Experiment finds yoghurt can lower house temperature
But there would likely have been few trying out one university lecturer's alternative method to lower the temperature in a building.
Dr Ben Roberts, a senior lecturer in healthy buildings at Loughborough University, said applying yoghurt to the outside of windows can lower the temperature by up to 3.5C (38F).
He has pointed to the results of a month-long experiment to show the method has brought results.
He said: "We can't get houses to cool down during the day.
"That's a real problem for a lot of people, so we've started to look at shading solutions, stopping sun getting into your house during the day."
In May, Dr Roberts and PhD student Niloo Todeh-Kharman conducted an experiment on two identical test houses at Loughborough University by putting yoghurt on the windows of one, but not the other.
The experiment found the indoor temperature of the house with yoghurt on the windows was on average 0.6C (33F) cooler, but up to a maximum of 3.5C cooler when it was "hot and sunny".
According to Dr Roberts, the yoghurt forms a thin film on the window itself and reflects some of the incoming solar radiation as it is a light colour.
This means not as much heat passes through the window.
He told the BBC the yoghurt smells for "30 seconds when drying" but that as soon as it has dried "the smell disappears".
Dr Roberts said the idea came from a conversation with Tom Greenhill, the author of the Heatwave Toolkit website, who was thinking of "low-cost ways" which could stop overheating.
He added Mr Greenhill tried putting yoghurt on his own house but that it had never been tested.
For their experiment, the scientists at Loughborough University used a supermarket-brand of Greek yoghurt that has a fat percentage of about 10%.
When he saw the results of the investigation, Dr Roberts said he was "quite surprised" as he did not think it would be "that effective".
He added that when they carried out experiments with tinfoil - which blocks "pretty much" all of the incoming sun's heat - they saw a maximum temperature drop of 5 to 6C (41-42.8F), so he was "pleasantly surprised" with the results from the yoghurt experiment.
Dr Roberts said: "It shows the importance of treating windows and heat shielding solutions for windows to reduce overheating."
"We see a lot of excess summer deaths, so very simply if you can keep your home cooler we'll reduce the number of excess summer deaths happening and we can improve people's health and wellbeing," he added.
Dr Zoe De Grussa, research manager at the Chartered Institute of Building Service Engineers, added: "It's not your everyday hack, I would say, but anything you can do to put on the outside of windows is going to be of benefit to stopping sunshine coming in and heating up the internal environment."
Follow BBC Leicester on Facebook, on X, or on Instagram. Send your story ideas to eastmidsnews@bbc.co.uk or via WhatsApp on 0808 100 2210.
As UK faces third heatwave, is this 'just summer'?
Loughborough University
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Older Breast Cancer Patients Face Inconsistent Bone Care
TOPLINE: Bone health management for older women with breast cancer receiving aromatase inhibitors (AIs) varied substantially across five UK hospitals. Despite the higher risk for fractures, women older than 80 years were less likely to receive DEXA scans or bisphosphonates, highlighting the urgent need for standardised bone monitoring and treatment in frail older patients. METHODOLOGY: This secondary analysis of the multicentre Age Gap study included 529 women (age, ≥ 70 years) with oestrogen receptor-positive early breast cancer who received AIs, either as primary or adjuvant treatment, at five hospitals in the UK. Researchers collected comprehensive data including the type of endocrine therapy, DEXA scan results, bisphosphonate usage, calcium and vitamin D supplementation, and the incidence of fractures during or after AI therapy. Frailty was assessed using a modified Rockwood Frailty Index, with scores being calculated across 75 variables to categorise patients as robust (< 0.08), prefrail (0.08-0.25), or frail (> 0.25). TAKEAWAY: Overall, 67% of patients had baseline DEXA scans. Of these, 42% were osteopenic and 18% osteoporotic. Scans were more common in 70- to 79-year-olds than in those aged 80 years or older and in women undergoing surgery than in those undergoing primary endocrine therapy, with marked variation across centres (P < .001 for all). Among patients receiving AI therapy, 43% were prescribed bisphosphonates, especially those who had surgery (hazard ratio [HR], 1.36; P = .04) and those aged 70-79 years (HR, 1.31; P = .02); 33% had vitamin D plus calcium along with bisphosphonates. During follow-up, 23% of patients had fractures, with significant variation across centres (P = .02), and 38% of these patients had received prior bisphosphonates. Although 94% of patients were frail or prefrail, frailty did not correlate with baseline hip (P = .10) or spine (P = .89) T scores. Bisphosphonates plus AIs were prescribed in 70% of non-frail participants vs 43% of prefrail and 47% of frail participants (P = .02). IN PRACTICE: "Patient's age and general health influence bone health decision making, with older and frailer patients often receiving non-standard care. Despite national and international recommendations, there is still wide variation in bone health management, highlighting the need for further education and standardised bone health care in older women with breast cancer," the authors wrote. SOURCE: This study was led by Elisavet Theodoulou, University of Sheffield, Sheffield, England. It was published online on July 18, 2025, in the Journal of Geriatric Oncology. LIMITATIONS: The study's inclusion of only five hospital sites limited the ability to draw broader conclusions about bone health management practices across a wider range of centres. Additionally, the interpretation of the results was complicated by the introduction of adjuvant bisphosphonates during the study period, making the cohort unstable in terms of bisphosphonate usage indications. DISCLOSURES: The Age Gap study was supported by the National Institute for Health and Care Research Programme Grants for Applied Research. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
an hour ago
- Medscape
Low Vitamin D May Raise COVID-19 Hospitalisation Risk
TOPLINE: An analysis of over 150,000 participants found that insufficient and deficient levels of vitamin D were associated with an increased risk for COVID-19 hospitalisation but not with the risk for COVID-19 infection; however, no significant associations were found among participants with a prior cancer diagnosis. METHODOLOGY: Researchers in London used data from the UK Biobank cohort to assess the association between levels of vitamin D (insufficient and deficient vs normal) and both COVID-19 infection and hospitalisation. They included a total of 151,543 participants (mean age, 56 years; 53% women), with a subset of 24,400 participants diagnosed with cancer prior to 2019. Serum vitamin D levels were measured at baseline between 2006 and 2010 (deficiency, < 24 nmol/L; insufficiency, 25-50 nmol/L; and normal, > 50 nmol/L); all had at least one positive COVID-19 polymerase chain reaction test. Endpoints were first COVID-19 infection (measured using the positive polymerase chain reaction test result) and COVID-19 hospitalisation (measured using hospital admission records). TAKEAWAY: Among overall participants, 14% had at least one positive COVID-19 test result, of whom 11% were hospitalised; in the cancer cohort, 11% of participants tested positive for COVID-19 and 14% of them were hospitalised. Vitamin D insufficiency and deficiency were associated with 19% and 36% higher odds of COVID-19 hospitalisation, respectively, than normal levels of vitamin D (P < .001 for both); however, no association was found between low levels of vitamin D and COVID-19 infection. Sensitivity analyses showed that among Black and Asian participants, low levels of vitamin D were linked to an increased risk for COVID-19 infection but not to increased hospitalisation rates. Among the subset of patients with cancer, levels of vitamin D were not significantly associated with COVID-19 outcomes. IN PRACTICE: "[The study] results highlight the complex role of VitD [vitamin D] in COVID-19 outcomes and the varying impact it has across different population subgroups," the authors wrote. SOURCE: This study was led by Maria J. Monroy-Iglesias, Transforming Outcomes through Research, Centre for Cancer, Society, and Public Health, School of Cancer and Pharmaceutical Sciences, King's College London, London, England. It was published online on July 18, 2025, in PLoS One. LIMITATIONS: Vitamin D levels were measured at baseline (between 2006 and 2010) over a decade before the COVID-19 pandemic, which may have led to the misclassification of participants' vitamin D status. This study could not account for seasonal variations in vitamin D levels. Subgroup analyses were limited by small sample sizes. The study cohort was not fully representative of the UK population, and potential bias may have arisen from differential access to COVID-19 testing. DISCLOSURES: This study did not receive any specific funding. The authors declared having no competing interests. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
2 hours ago
- Yahoo
Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies
· Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements. Ingelheim, Germany, Tampa, Florida, USA, and Belfast, Northern Ireland, UK [28 July 2025] – Boehringer Ingelheim and Re-Vana Therapeutics, a US and UK based developer of ocular therapeutics and ocular drug delivery technologies, today announced a strategic collaboration and license agreement that aims to develop first-in-class extended-release therapies for eye diseases. Globally, millions of people living with eye health conditions face a progressive decline in their independence and connection to the world due to vision loss. With its diverse pipeline in eye health, which includes four assets in Phase II, Boehringer Ingelheim is committed to preserving the retina, protecting people's way of life and preventing vision loss. Treating ophthalmic diseases often requires frequent injections directly into the eye, which can be very burdensome for patients. Re-Vana's drug delivery technology is designed to release treatments slowly over six to 12 months, aiming to drastically reduce how often patients need injections. Lowering the treatment burden could lead to higher treatment compliance, and potentially result in better therapeutic outcomes. Boehringer Ingelheim will explore combining this technology with its unique pipeline in eye health. 'We're looking forward to team up with Re-Vana to push the boundaries of what's possible in eye health,' said Nedim Pipic, Global Head of Mental Health, Eye Health and Emerging Areas at Boehringer Ingelheim. 'Together, we want to tackle the limits of today's treatments – aiming to help people keep their sight, with fewer injections. This partnership is a bold step forward in our mission to protect vision and ease the burden on patients.' 'The strategic collaboration with Boehringer Ingelheim marks a transformational moment for Re-Vana,' said Michael O'Rourke, Re-Vana Chief Executive Officer. 'By combining our extended-release platform with Boehringer Ingelheim's world-class research and development capabilities and eye health pipeline, we strive to bring forward a new generation of long-acting treatments for eye diseases that offer clinical and quality-of-life benefits for patients.' Under the collaboration, Boehringer Ingelheim aims to add up to three projects per year across therapeutic modalities. The companies will jointly oversee Re-Vana's feasibility and development activities for the extended-release programs, with Boehringer Ingelheim assuming sole responsibility for clinical development, regulatory approval, and global commercialization of the products. The terms of the agreement grant Boehringer Ingelheim target exclusivity, and provide for upfront, development, regulatory and commercial milestone payments to Re-Vana, with total potential deal value exceeding $1 billion for the initial three targets, in addition to royalty payments on net sales. Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at (Global) or (UK). About Re-Vana Therapeutics Re-Vana Therapeutics Ltd, founded in 2016 as a spin-out from Queen's University Belfast, is an ocular therapeutics and innovative ocular drug delivery company based in Belfast, Northern Ireland, and a wholly owned subsidiary of Re-Vana Holding, Inc., Tampa, Florida. Re-Vana is venture backed with leading US Ophthalmic investors including Visionary Ventures, ExSight Ventures, InFocus Capital Partners and UK investors including QUBIS, TechStart Ventures, Invest Northern Ireland and Clarendon Fund Managers. Re-Vana is currently raising a Series B round for their sustained release anti-VEGF asset. Learn more at Intended Audiences Notice This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business. Media Contacts Boehringer Ingelheim: Dr. Reinhard MalinBoehringer Ingelheim Corporate Center GmbH Innovation Unit/Bio Comms, Corp. Affairs Media + PR press@ Linda RuckelBoehringer IngelheimInnovation Unit Re-Vana: Michele Gray Gray Communications, LLCMichele@ 917 449 9250Sign in to access your portfolio
